Logo KMS TEAM
Precise execution

MC Services is...

Client News

… an international Corporate Communications and Investor Relations firm providing high-level consultancy with targeted services and support for transaction-oriented assignments throughout Europe and the United States.

read more

Life Sciences Authority Andreas Burckhardt joins MCS Team

MC Services announces the appointment of Andreas Burckhardt as Executive Director Corporate Broking, effective as of April 1, 2013. The appointment expands MC Services’ Investor Relations offering to now include international investor access, financial transactions and investor roadshow management. MC Services is building this platform to support clients to meet the changing environment in the capital markets and the growing need for greater access to local and international healthcare investors.

read more

„Annual Report 2012“

On September 28, 2012 MC Services and KMS TEAM hosted their seminar on Financial Communications at the offices of KMS TEAM in Munich. In a one-day seminar with Prof Jörg Baetge and other renowned financial and communications experts, relevant trends and innovations on annual reports were introduced and the challenges of Financial Communications were discussed with all participants.

read more

 

 

 

Agennix AG Announces Liquidation

www.agennix.com

SuppreMol Raises € 9.5 million in Extended Series D Financing Round

www.suppremol.com

4SC's partner Yakult Honsha starts clinical Phase I/II study with cancer compound resminostat in liver cancer in Japan

www.4sc.de

SYGNIS licenses amplification buffer to QIAGEN

www.sygnis.de

Results of Comparative Study between Epigenomics Epi proColon® and FIT to be Presented at Digestive Disease Week

www.epigenomics.com

SYGNIS reports results for the first quarter of 2013

www.sygnis.de

Medigene reports financial results for the first quarter of 2013

www.medigene.com

MagForce to Present at Two Investor Conferences in the US

www.magforce.de

4SC significantly improves operating result in first quarter of 2013 and resolves to focus its development strategy

www.4sc.de

MorphoSys Initiates Phase 2 Study of Anti-CD19 Antibody MOR208 in Non-Hodgkin's Lymphoma

www.morphosys.com